Jaguar Health Reports Early Crofelemer Data in Short Bowel Syndrome
Jaguar Health presented preliminary results from an open-label pilot study of oral crofelemer in adults with Type 1 short bowel syndrome and intestinal failure. The study is testing whether the drug reduces ostomy output in patients who need parenteral support. Some participants showed changes in ostomy volume, and no significant adverse events were reported.
Jaguar Health's Napo Pharmaceuticals reported interim findings from an open-label trial of liquid crofelemer in adults with Type 1 short bowel syndrome and intestinal failure. Participants received 3 mg/kg three times daily for 12 weeks while continuing stable parenteral support. The study aims to enroll six people; four have completed it.
Among completers, two averaged a 5% drop in ostomy volume at week 12, while three averaged a 23% rise after stopping treatment. One had a 9% reduction in parenteral support volume, and three showed an 88% average improvement in urinary output that persisted four weeks after cessation. Investigators did not report significant adverse events.
If larger trials confirm benefit, crofelemer could offer an oral option to reduce ostomy output and possibly parenteral support needs for some adults with Type 1 short bowel syndrome and intestinal failure. That may ease daily management burdens for patients and caregivers and could influence treatment planning. However, preliminary open-label data from few participants cannot establish efficacy or broad impact; randomized results expected later may clarify.